Published on 07.11.16 in Vol 5, No 4 (2016): Oct-Dec
A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)
Background: Guillain-Barré syndrome (GBS) is an immune-mediated neuropathy that causes acute flaccid paralysis. Immunoglobulin and plasma exchange are established treatments for GBS; however, a substantial number of patients, particularly those with severe disease, have poor recovery and residual deficits. Recent studies suggest that complement activation plays a pivotal role in GBS-associated axonal degeneration, and eculizumab is a humanized monoclonal antibody that specifically binds to complement component 5 and potently inhibits complement activation.
Objective: This clinical trial aims to evaluate the efficacy and safety of eculizumab, a humanized monoclonal antibody directed against complement component 5, for treatment of GBS.
Methods: The Japanese Eculizumab Trial for GBS (JET-GBS) is a prospective, multicenter, placebo-controlled, double-blind, randomized phase II study conducted at 13 tertiary neurology centers and is funded by the Japan Agency for Medical Research and Development. A total of 33 GBS patients unable to walk independently within 2 weeks from symptom onset (Hughes functional grade 3-5) were randomized at a 2:1 ratio to receive either intravenous eculizumab (900 mg/day) or placebo once weekly for 4 weeks, followed by 20 weeks of follow-up. The primary endpoint for efficacy is the proportion of patients who regain their ability to walk without aid at 4 weeks after the first dose of the study treatment, while primary safety outcomes are the incidence of adverse events and serious adverse events during the trial.
Results: Enrollment for the trial began in August 2015. This trial is still ongoing. All participants have been enrolled, and follow-up will be completed in October 2016.
Conclusions: This study is the first to investigate the efficacy and safety of eculizumab for GBS. In case of a positive result, we will plan a phase III trial to investigate this issue in a larger number of patients.
ClinicalTrial: UMIN Clinical Trials Registry UMIN 000018171; https:/upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function= brows&action=brows&type=summary&language=J&recptno=R000020978 (Archived by WebCite at http://www.webcitation.org/ 6lTiG8ltG). Clinical Trials.gov NCT02493725; https://clinicaltrials.gov/ct2/show/NCT02493725 (Archived by WebCite at http://www.webcitation.org/6lVJZXKSL)
JMIR Res Protoc 2016;5(4):e210
- Guillain-Barré syndrome;
- complement activation;
- clinical trial;
- antiganglioside antibody
Crowdfunding campaign to support this specific research
We help JMIR researchers to raise funds to pursue their research and development aimed at tackling important health and technology challenges. If you would like to show your support for this author, please donate using the button below. The funds raised will directly benefit the corresponding author of this article (minus 8% admin fees). Your donations will help this author to continue publishing open access papers in JMIR journals. Donations of over $100 may also be acknowledged in future publications.
Suggested contribution levels: $20/$50/$100
Guillain-Barré syndrome (GBS) is the most common cause of acute tetraparalysis in developed countries [, ]. GBS occurs in all age groups, and the annual incidence is reported to range from 0.81 to 1.89 per 100,000 persons [ ]. Although the efficacies of intravenous immunoglobulin (IVIg) and plasma exchange have been demonstrated in randomized controlled studies [ , ], GBS still carries nonnegligible mortality and morbidity [ ]. Mortality within the first year is approximately 4% [ ]. Recovery takes several months or years, and approximately 14% of GBS patients show severe persistent disability at one year after onset [ ].
GBS is classified into two major subtypes: acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN). Over the past two decades, major advances have been made in understanding the pathophysiology of AMAN . It is now established that AMAN is caused by molecular mimicry of human gangliosides by an antecedent pathogen and ensuing antiganglioside antibody-mediated attack on the axolemma. In an animal model induced by antiganglioside antibodies, complement activation contributed to disruption of the nodal and paranodal molecular architectures, leading to acute paralysis and residual deficits [ - ]. Furthermore, nafamostat mesilate, a synthetic serine protease inhibitor with anticomplement action, prevented nerve damage in a GBS rabbit model [ ].
Eculizumab is a humanized monoclonal antibody that specifically binds to complement component 5 (C5) and suppresses its cleavage into active chemotaxis mediator C5a and attacks complex component C5b, thereby inhibiting membrane attack complex (MAC) formation [, ]. Eculizumab has been approved for treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome [ , ], disorders wherein intravascular hemolysis is induced by complement activation. The efficacy of eculizumab for GBS has been shown in a mouse model mediated by antiganglioside antibody [ ]. Eculizumab blocks the formation of MAC associated with terminal axonal and glial injury at the neuromuscular junction and prevents respiratory paralysis [ ]. We, therefore, designed the Japanese Eculizumab Trial for Guillain-Barré syndrome (JET-GBS) study to investigate the efficacy and safety of eculizumab in GBS patients.
Trial Design Overview
This is a prospective, multicenter, placebo-controlled, double-blind, randomized phase II trial in patients with GBS. A schematic depiction of the trial design is presented in. The trial is composed of 3 periods: the screening period, investigation product (IP) administration period, and post-IP period. Screening is conducted within 5 days of randomization to assess eligibility and collect baseline data. Eligible patients were defined as those unable to walk independently (Hughes functional grade [FG] 3-5) within 2 weeks from the onset of weakness, because such patients have a higher risk of progression. They are randomized to receive either eculizumab or placebo at a 2:1 ratio. Eculizumab (900 mg/day) or matching placebo is administered intravenously once a week for a total of 4 doses (day 1, day 8, day 15, day 22) in conjunction with IVIg, the standard treatment for GBS (400 mg/kg daily for 5 consecutive days). IVIg can be readministered if patients show deterioration after initial improvement or stabilization (treatment-related fluctuation) following day 15. Patients are monitored periodically up to week 24. The primary endpoint for efficacy is the proportion of patients who reach FG 2 or lower (able to walk without aid) at day 29 (week 4). The primary endpoints for safety are the proportion and severity of adverse events (AEs) and serious adverse events (SAEs).
GBS patients who meet all of the following inclusion criteria and none of the listed exclusion criteria are enrolled (see). Diagnosis of GBS is made with reference to the National Institute of Neurological Disorders and Stroke criteria [ ].
Investigational Product (Eculizumab or Placebo)
Eculizumab (900 mg/day) or placebo is administered intravenously once a week for 4 weeks in patients who are being considered for, or already on IVIg treatment. The first dose of the IP is to be started before the last dose of IVIg. The patients are to be monitored by the medical staff for at least 1 hour following eculizumab/placebo infusion, because administration of eculizumab may result in infusion reactions. Administration is interrupted if severe infusion reactions occur.
Inhibition of the terminal complement complexes predisposes patients to infections by encapsulated bacteria, especially N meningitidis. Therefore, all enrolled patients must receive antibiotic prophylaxis against N meningitidis for 8 weeks from the last dose of the IP.
The efficacy and safety of eculizumab will be assessed by the following endpoints. The primary efficacy endpoint is the proportion of patients who reach FG 2 or lower (able to walk without aid) at week 4, and the safety endpoints are the proportion and severity of AEs/SAEs during the trial.
The secondary endpoints include the proportion of patients with improvement of 1 or more Hughes functional grades from baseline at each visit, proportion of patients who are able to walk unaided at each visit, duration required for improvement by at least 1 Hughes functional grade, proportion of FG 1 or 0 at week 24, change from peak FG at each visit, clinically relevant improvement in the Rasch-built Overall Disability Scale (R-ODS) score and the Overall Neuropathy Limitations Scale (ONLS) score at each visit, proportion of ventilatory support, duration of ventilatory support, occurrence of relapse, overall survival, changes in grip strength, manual muscle testing score, median and ulnar nerve conduction parameters, vital capacity respectively from baseline at each visit, and proportion of IVIg readministration.
This study is also investigating antiganglioside antibodies, concentration of serum eculizumab, and serum hemolytic activity as exploratory endpoints. The data of antiganglioside antibodies assay will be used to determine the subtype of GBS, and the results of eculizumab concentration and hemolytic activity will be used to obtain exploratory data on the efficacy of eculizumab.
Study Visits and Assessments
The schedule for the study visits and assessments are summarized inand . Patients are assessed weekly for efficacy and safety during the 4-week IP administration period and on week 6, 8, 12, 16, and 24 during the 20-week post-IP period. Patients are requested to record their FG score independently using a diary until they show an improvement by one grade. If all 4 administrations of the IP cannot be completed due to AEs or other contingencies, patients remain in the trial and tests/assessments will be performed on the patients according to the trial schedule unless they meet the withdrawal criteria.
|Time window (days)||−5||±2||±2||±2||±7|
|Demography and medical history||X|
|Nerve conduction study||X||X|
|Clinical lab test (blood test/urine test)||X||X||X||X||X|
|Eculizumab concentration/hemolytic activity||X||X||X|
|Pregnancy test (urine test)h||X|
|Concomitant drug/therapy review||X||X||X||X||X||X|
aIP: investigational product.
bChemoprophylaxis will begin at the start of eculizumab infusion on day1 and be continued till 8 weeks from the last dose of eculizumab.
cFG: Hughes functional grade.
dONLS: overall neuropathy limitations score.
eMMT: manual muscle testing.
fR-ODS: Rasch-built overall disability scale.
hPregnancy tests must be performed on all women of child bearing potential at the specified time points and verified to have a negative result. Pregnancy test may also be performed at any visit at the investigator’s discretion.
iVital signs: blood pressure, heart rate, body temperature.
|Period||Post-IPa administration (outpatient)||Early termination||Follow-up visitb|
|Time window (days)||±7||±7||±7||±7||±7||+7||+7|
|Demography and medical history|
|Nerve conduction study||X||X||X|
|Clinical lab test (blood test/urine test)||X||X||X||X||X||X||X|
|Eculizumab concentration/hemolytic activity||X|
|Pregnancy test (urine test)i||X||X||X|
|Concomitant drug/therapy review||X||X||X||X||X||X||X|
aIP: investigational product.
bIf a patient withdraws from the trial within 8 weeks after the last IP administration, a final follow-up visit will be performed at 8 weeks after the last IP administration for safety assessment.
cChemoprophylaxis will begin at the start of eculizumab infusion on day1 and be continued till 8 weeks from the last dose of eculizumab.
dFG: Hughes functional grade.
eONLS: overall neuropathy limitations score.
fMMT: manual muscle testing.
gR-ODS: Rasch-built overall disability scale.
iPregnancy tests must be performed on all women of child bearing potential at the specified time points and verified to have a negative result. Pregnancy test may also be performed at any visit at the investigator’s discretion.
jVital signs: blood pressure, heart rate, body temperature.
Data Management, Monitoring and Auditing
Study data is recorded in the electronic case report form (eCRF) of Medidata Rave, which was configured for this study by the data management division at Chiba University Hospital Clinical Research Centre. The eCRF data maintain anonymity and identify participating patients by their assigned identification codes. Independent monitors ensure that the study is properly conducted at each site in accordance with the protocol and good clinical practice and verify that the contents of case reports and other reports are current and accurate. The monitors and data managers assure the quality of the data at each stage of handling. Auditors who are independent from all divisions conducting the trial perform audits of the clinical trial sites and verify appropriate quality assurance.
Reporting for Adverse Events and Serious Adverse Events
All AEs are recorded on the AE page of the eCRF. The investigator at each site endeavors to obtain the outcome and severity of all AEs. AEs are reported from the time of informed consent to the last trial visit (week 24); however, SAEs with a causal relationship to the IP are monitored until resolution if possible. All SAEs are reported to all investigators and assessed through a Web-based AE reporting system that has been developed by the Japan Medical Association, Centre for Clinical Trials. SAEs that have not been reported previously are reported to the Pharmaceuticals and Medical Devices Agency.
Sample Size Calculation
The sample size was based on the results from our previous study  and our historical database of GBS patients. For the primary endpoint of efficacy, we estimated that the threshold value for Hughes FG 2 or lower at week 4 would be 50% and the expected value 80%. A sample size of 20 patients in the eculizumab group is required to achieve statistical significance level of 5% (1-sided) at 80% power. To allow for a 10% dropout rate, total sample size in the eculizumab group is 22. Additionally, 11 patients will be randomly assigned to the placebo control to collect efficacy and safety data. The total sample size was set at 33.
Eligible patients who provided informed consent are registered for study enrollment and are randomized to the eculizumab or placebo arm at a 2:1 ratio via a Web-based system developed by ADJUST Co Ltd. Allocation is performed using the minimization method with biased coin assignment [, ] balancing for FG score (FG=3 or FG≥4) and age (younger than 60 years or 60 years and older).
Each vial of IP contains 300 mg of eculizumab or placebo. The placebo has an identical external appearance to that of eculizumab. All participating patients, investigators, study coordinators, data managers, and outcome assessors remain blinded to group assignment during the trial. In order to maintain blinding, measurements of serum 50% hemolytic complement activity are prohibited during the trial. The levels of antiganglioside antibodies, eculizumab concentrations, and hemolytic activities in serum are measured at a central laboratory and the results are masked to all patients and study personnel during the trial.
Statistical analyses and reporting of this trial will be conducted in accordance with the Consolidated Standards of Reporting Trials statement guidelines with the primary analyses based on the intent-to-treat principle without imputing any missing observations. All efficacy analyses will be primarily based on the full analysis set, which includes all patients who have received at least one dose of the study treatment.
The primary endpoint for efficacy is the proportion of patients with FG≤2 at week 4. We hypothesized that response threshold at week 4 would 50% as H0 (null hypothesis), whereas the expected response rate would be 80% as H1 (alternative hypothesis). The exact 90% confidence interval will be calculated by the binominal distribution for the response rate of each treatment group. The confidence limits of the confidence interval will be assessed against the response threshold; however, in primary analysis, we will not perform a statistical testing for comparison of treatment groups.
For the patient characteristics, summary statistics were constructed using frequencies and proportions for categorical data and means and SDs for continuous variables. Patient characteristics were compared using a Fisher exact test for categorical outcomes and a Student t test or the Wilcoxon rank sum test for continuous variables, as appropriate. All comparisons were planned, and all P values are 2-sided. A value of P<.05 is considered statistically significant. Subgroup analysis will be performed for safety and efficacy depending on GBS subtype, baseline FG, and electrodiagnosis.
All statistical analyses are performed using SAS software version 9.4 (SAS Institute) and the R statistical program version 2.13 (The R Foundation). All statistical analyses are described in the statistical analysis plan, which will be fixed prior to database lock.
Ethics and Dissemination
Research Ethics Approval and Protocol Amendments
The study protocol was approved by the institutional review board (IRB) at each site before the start of the trial. Substantial amendments of the study protocol must be approved by each IRB. The trial was registered at the University Hospital Medical Information Network clinical trials registry  and ClinicalTrials.gov [NCT02493725].
All participants are fully informed about the nature, purpose, possible risks, and benefits of the study with both oral and written information approved by all IRBs. Participants are notified that they are free to withdraw from the study at any time. The participants are given the opportunity to ask questions and allowed time to consider the information provided before consent. The participant’s signed and dated informed consent is obtained before conducting any study procedures. A copy of the consent document and explanation document is given to the participant and the original copy of the consent document is retained at the clinical trial site.
The trial started enrollment in August 2015. All 34 participants have been enrolled according to plan. This trial is still ongoing. Follow-up will be completed in October 2016.
The JET-GBS is the first phase II trial to investigate the efficacy and safety of a monoclonal antibody specifically binding C5 for the treatment of GBS. Given that complement activation and MAC deposition is known to play a pivotal role in GBS-associated nerve degeneration [, , ], we speculate that eculizumab can effectively prevent nerve injury, thereby accelerating recovery from GBS.
The efficacies of plasma exchange and IVIg for GBS treatment were first established in the 1980s and 1990s [, ], but subsequent clinical trials have failed to demonstrate beneficial effects of alternative therapeutic approaches such as interferon-β1a [ ], brain-derived neurotrophic factor [ ], and mycophenolate mofetil [ ]. Thus, IVIg and plasma exchange are still the mainstays of GBS treatment, with IVIg preferred because of its greater convenience and availability. However, new treatment options are necessary because the prognosis is still far from satisfactory for many patients [ ].
There are several limitations to this study. First, the number of enrolled patients is small as this trial was designed to provide proof of concept rather than to assess the superiority of different treatments. If this study demonstrates efficacy and safety for GBS, we will plan a phase III trial to confirm its effectiveness and safety in a larger number of patients. Second, the pathogenic mechanism targeted by eculizumab (complement activation) appears active only in conjunction with antiganglioside antibody related to AMAN [, ], as no study has clearly demonstrated a contribution of complement activation to demyelination or axonal degeneration in AIDP. However, the finding of C3d and C5b-9 deposits along the outer surface of Schwann cells in an autopsy study of AIDP suggests that eculizumab may also be effective for AIDP [ ]. In the current study, we are also planning to investigate whether GBS subtype (AMAN or AIDP) or the presence of antiganglioside antibodies can influence the efficacy of eculizumab. Third, 3% of Japanese have a mutation in C5 that renders them resistant to eculizumab therapy. It might substantially affect results of this study.
There has been no substantial progress in GBS treatment over the last two decades. However, recent progress in understanding GBS pathophysiology and the development of novel biological agents targeting these pathogenic pathways could enable alternative approaches to mitigate nerve injury in GBS. The present clinical trial based on a specific pathogenic mechanism of GBS may pave the way for improved GBS therapies.
We would like to thank Eri Kobayashi and Kazue Namiki (Clinical Research Center, Chiba University Hospital, Chiba) for their practical input on the protocol. This work is supported by the Japan Agency for Medical Research and Development under the agency’s Early-Phase/Exploratory or International-Standard Clinical Research Program (project number: J16JK00019).
Conflicts of Interest
The investigational product is provided by US-based Alexion Pharmaceuticals Inc under the Global Investigator-Sponsored Research Program. The interest profile of this trial is to be reviewed and approved by the conflict of interest committees of the participating sites, all in accordance with the applicable regulatory requirements and guidelines, and potential conflicts addressed through conflict of interest management and integrity assurance efforts.
SaK and SuK conceived the study and are responsible for managing the study as co-chief investigators. NY and SM wrote the protocol and manuscript. YaS and KN contributed to statistical input, outlining of statistical methods, and analysis. KK contributed to protocol design and conduct of the study. YuS, YI, HA, and TS contributed to an intensive survey on GBS demography for enhancing patient recruitment. HH provided guidance on overall direction of the study.
The JET-GBS group consists of Dr Tadashi Kanouchi (Tokyo Medical and Dental University, Tokyo), Dr Michi Kawamoto and Dr Junko Ishii (Kobe City Medical Centre General Hospital, Kobe), Dr Norito Kokubun (Dokkyo Medical University, Tochigi), Dr Ray Masuda and Dr Takahiro Shimizu (Kitasato University School of Medicine, Kanagawa), Dr Motoi Kuwahara (Faculty of Medicine, Kindai University, Osaka-Sayama), Dr Hidenao Sasaki and Dr Makoto Hirotani (Hokkaido University Graduate School of Medicine, Sapporo), Dr Hiroshi Takazaki (National Defense Medical College, Saitama), Dr Shigeaki Suzuki (Keio University School of Medicine, Tokyo), Dr Naoko Matsui (Graduate School of Medical Sciences, Tokushima University, Tokushima), Dr Jun Shimizu (The University of Tokyo Graduate School of Medicine, Tokyo), and Dr Ryo Yamasaki and Dr Hidenori Ogata (Graduate School of Medical Sciences, Kyushu University, Fukuoka). All members of the JET-GBS group made significant contributions to trial implementation. All authors critically reviewed the study protocol and the manuscript and gave approval for this publication.
- Osler LD, Sidell AD. The Guillain-Barre syndrome; the need for exact diagnostic criteria. N Engl J Med 1960 May 12;262:964-969. [CrossRef] [Medline]
- Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005 Nov 5;366(9497):1653-1666. [CrossRef] [Medline]
- Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36(2):123-133 [FREE Full text] [CrossRef] [Medline]
- Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2014;CD002063(9). [CrossRef] [Medline]
- Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012;CD001798(7). [CrossRef] [Medline]
- Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2012 Jul;83(7):711-718. [CrossRef] [Medline]
- Kuwabara S, Yuki N. Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol 2013 Dec;12(12):1180-1188. [CrossRef] [Medline]
- Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007 Apr 11;27(15):3956-3967 [FREE Full text] [CrossRef] [Medline]
- Susuki K, Yuki N, Schafer DP, Hirata K, Zhang G, Funakoshi K, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 2012 Jan;233(1):534-542 [FREE Full text] [CrossRef] [Medline]
- Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol 2008 Dec 15;205(1-2):101-104. [CrossRef] [Medline]
- Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012 Nov;8(11):643-657. [CrossRef] [Medline]
- Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007 Nov;25(11):1256-1264. [CrossRef] [Medline]
- Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013 Jun 6;368(23):2169-2181. [CrossRef] [Medline]
- Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004 Feb 5;350(6):552-559. [CrossRef] [Medline]
- Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008 May;131(Pt 5):1197-1208 [FREE Full text] [CrossRef] [Medline]
- Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990;27 Suppl:S21-S24. [Medline]
- Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, et al. Antiganglioside antibodies are associated with axonal Guillain-Barre syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012 Jan;83(1):23-28. [CrossRef] [Medline]
- Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975 Mar;31(1):103-115. [Medline]
- Brown S, Thorpe H, Hawkins K, Brown J. Minimization: reducing predictability for multi-centre trials whilst retaining balance within centre. Stat Med 2005 Dec 30;24(24):3715-3727. [CrossRef] [Medline]
- Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome. Neurology 2003 Nov 11;61(9):1282-1284. [Medline]
- Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barre syndrome: a pilot study. Eur J Neurol 2000 Jul;7(4):423-426. [Medline]
- Garssen MP, van Koningsveld KR, van Doorn PA, Merkies IS, Scheltens-de Boer M, van Leusden JA, et al. Treatment of Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry 2007 Sep;78(9):1012-1013 [FREE Full text] [CrossRef] [Medline]
- Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996 May;39(5):625-635. [CrossRef] [Medline]
|AIDP: acute inflammatory demyelinating polyneuropathy|
|AE: adverse event|
|AMAN: acute motor axonal neuropathy|
|C5: complement component 5|
|eCRF: electronic case report form|
|FG: Hughes functional grade|
|GBS: Guillain-Barré syndrome|
|IP: investigational product|
|IRB: institutional review board|
|IVIg: intravenous immunoglobulin|
|JET-GBS: Japanese Eculizumab Trial for Guillain-Barré syndrome|
|MAC: membrane attack complex|
|ONLS: Overall Neuropathy Limitations Scale|
|R-ODS: Rasch-built Overall Disability Scale|
|SAE: serious adverse event|
Edited by G Eysenbach; submitted 03.09.16; peer-reviewed by J Hao, BP Morgan; comments to author 21.09.16; accepted 04.10.16; published 07.11.16
©Nobuko Yamaguchi, Sonoko Misawa, Yasunori Sato, Kengo Nagashima, Kanako Katayama, Yukari Sekiguchi, Yuta Iwai, Hiroshi Amino, Tomoki Suichi, Takanori Yokota, Yoichiro Nishida, Nobuo Kohara, Koichi Hirata, Kazutoshi Nishiyama, Ichiro Yabe, Ken-Ichi Kaida, Norihiro Suzuki, Hiroyuki Nodera, Shoji Tsuji, Haruki Koike, Jun-Ichi Kira, Hideki Hanaoka, Susumu Kusunoki, Satoshi Kuwabara, JET-GBS Group. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 07.11.2016.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.